News

Nexus Pharmaceuticals Inc., woman-owned, privately held, US-based healthcare company, announced an agreement with the village of Pleasant Prairie, Wisconsin to build an industry-leading…
Read More...

Jazz Pharmaceuticals plc announced that the company has signed a definitive agreement under which Jazz has acquired Redx Pharma's (Redx) pan-RAF inhibitor program for the potential…
Read More...

The U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for isatuximab for the treatment of patients with relapsed/refractory…
Read More...

Schreiner MediPharm, a Germany-based global provider of specialty pharmaceutical labeling solutions for over 65 years, has introduced a new sealing solution for tamper-proof closure of…
Read More...

Ligand Pharmaceuticals Incorporated announced positive top line results from a Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol program. The CE-Iohexol program was…
Read More...

Celsius Therapeutics, a company focused on the discovery and development of precision therapeutics for patients with autoimmune diseases and cancer, announced a collaboration with…
Read More...

MacroGenics, Inc. and I-Mab Biopharma (I-Mab) announced that the companies have entered into an exclusive collaboration and license agreement to develop and commercialize enoblituzumab.…
Read More...

Catalent, Inc. announced that it has significantly expanded the capacity of its global spray drying operations through an agreement with Sanofi Active Ingredient Solutions, an…
Read More...

ReachBio Research Labs (trade name under ReachBio LLC), a CRO specializing in primary cell assay services and products, is now offering off-target toxicity and linker stability assay…
Read More...

CytomX Therapeutics, a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody therapeutic…
Read More...

Lonza announced the completion of a $15M multi-phase expansion of its solid oral dose development and manufacturing capabilities and capacity at its Tampa, FL (USA) site. The expansion…
Read More...

NeuroRx, Inc., a clinical stage biopharma company focused on development of drugs targeting depression and suicidality, announced that it has initiated a pivotal Phase 2b/3 study for…
Read More...

Altimmune, Inc. announced that it has entered into an agreement to acquire Spitfire Pharma, Inc. (Spitfire) including its product candidate SP-1373 (to be renamed ALT-801), a potent…
Read More...

ImaginAb Inc., a clinical stage immuno-oncology imaging company, announced that it has entered into a non-exclusive license and collaboration agreement with Roche. Under the terms of…
Read More...

Mirati Therapeutics, Inc. announced a clinical collaboration agreement with Novartis to evaluate the combination of MRTX849, Mirati's investigational KRAS G12C inhibitor and TNO155,…
Read More...

Lyndra Therapeutics, the company making daily pills a thing of the past, has announced a partnership with Gilead Sciences, Inc. to develop and commercialize ultra-long-acting oral HIV…
Read More...

SunGen Pharma announced it has received its sixth ANDA approval from the US Food and Drug Administration (FDA). The sixth approved ANDA is for Methylprednisolone tablets, 4 mg. This…
Read More...

Ligand Pharmaceuticals Incorporated and SQ Innovation AG announced that the two companies have entered into long-term, exclusive commercial license and supply agreements for use of…
Read More...

BeiGene, Ltd. announced that the China National Medical Products Administration (NMPA, formerly known as the CFDA) has granted priority review status to the supplemental new drug…
Read More...

Grifols announced that Xembify, its new 20% subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration (FDA). Xembify is used to treat primary…
Read More...